Studies show Avandia reduces hepatic fat and increases subcutaneous fat without increasing intra-abdominal fat, a key factor in type 2 diabetes. The medication also decreases plasminogen activator inhibitor-1 levels, associated with cardiovascular risk factors.
The launch of Avandia provides patients with inadequate glycaemic control a new treatment option. Adding Avandia to metformin improves fasting plasma glucose levels in obese patients, reducing the risk of disease progression. This combination therapy also shows promise for patients with mild-to-moderate renal impairment.
Avandia targets both fundamental causes of type 2 diabetes by reducing insulin resistance and improving beta-cell function, providing enhanced glycaemic control. This dual therapeutic approach may delay disease progression and alter outcomes.
Type 2 diabetes accounts for 90% of all cases, with rising costs placing a strain on healthcare resources. Insulin usage and complications are key drivers of increased costs.
ReQuip significantly reduces the risk of levodopa-induced dyskinesia in Parkinson's disease patients. The five-year study shows that ReQuip monotherapy can reduce dyskinesia incidence by seven times and effectively control early PD symptoms.
A recent study found that nearly half of people with type 2 diabetes stop taking their oral anti-diabetic drugs (OADs), leading to a higher risk of complications such as blindness, amputation, and cardiovascular problems. The study revealed that individuals who discontinued treatment were almost three times more likely to die than thos...
A pan-European study found that type 2 diabetes in Europe is a significant healthcare burden, with total costs exceeding €29 billion and average individual costs more than double those of the general population. Preventing long-term complications through urgent action is crucial to reducing these costs.
Researchers found that rosiglitazone treatment improved glycaemic control and reduced risk factors for coronary heart disease in patients with type 2 diabetes. The medication also showed promise in reducing protein excretion and triglycerides, while improving lipid profiles.
Rosiglitazone reduces insulin resistance by 33% and improves pancreatic function in individuals with type 2 diabetes. The treatment also reduces insulin levels in the blood, potentially alleviating the need for regular insulin injections.
Studies suggest that involving individuals with diabetes in their care can improve quality of life and reduce complications. The results highlight the importance of patient education and empowering patients to make informed treatment choices.
A landmark study shows ReQuip reduces dyskinesia risk by 15-fold compared to L-dopa, with comparable symptom control and lower required doses. The treatment has improved patient outcomes and reduced CNS adverse experiences.